Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma

Gynecologic Oncology

Volumn 135, Issue 3, 2014, Pages 423-427

  Lessard Anderson, Collette R ^a,c   Handlogten, Kathryn S ^b   Molitor, Rochelle J ^b   Dowdy, Sean C ^a   Cliby, William A ^a   Weaver, Amy L ^a   Sauver, Jennifer St ^a   Bakkum Gamez, Jamie N ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c ALTRU HEALTH SYSTEM   (United States)

Author keywords

Fimbriectomy; Salpingectomy; Serous ovarian cancer; Serous primary peritoneal cancer; Tubal sterilization

Indexed keywords

ADULT; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; OVARY CARCINOMA; PARITY; PATIENT HISTORY OF HYSTERECTOMY; PERITONEUM CANCER; POPULATION BASED CASE CONTROL STUDY; PREGNANCY; PRIMARY PERITONEAL CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; UTERINE TUBE STERILIZATION; CASE CONTROL STUDY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MINNESOTA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RISK FACTORS; STERILIZATION, TUBAL;

EID: 84920720655     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.005     Document Type: Conference Paper

References (36)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin Jan 2014; 64(1):9-29 [Epub 2014 Jan 7].
2. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A Mar 6 2012;109(10):3921-6 [Epub 2012 Feb 13].
3. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res Mar 2007;5(1):35-44.
4. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modi fiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev Jan 2012;21(1):134-47 [Epub 2011 Dec 5].
5. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol Feb 2012;124(2):347-53.
6. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA Sep 1 2010;304(9):967-75.
7. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther 2007;11(3):133-44.
8. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol Oct 15 2007;166(8):894-901 [Epub 2007 Jul 26].
9. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev Feb 2009;18(2):601-10 [Epub 2009 Feb 3].
10. Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand Jun 2011; 90(6):559-63 [Epub 2011 Apr 15].
11. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol Feb 2001;127(2):73-9.
12. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germlinemutation status. Am J Surg Pathol Oct 2001;25(10):1283-9.
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med May 23 2002;346(21):1609-15 [Epub 2002 May 20].
14. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol Jan 1 2005;23(1):127-32.
15. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. for the Prevention and Observation of Surgical End Points Study Group N Engl J Med May 23 2002; 346(21):1616-22 [Epub 2002 May 20].
16. Finch A, et al. Clinical and pathologic fi ndings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecologic Oncology 2006;100.
17. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fi mbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol Feb 2007;31(2):161-9.
18. Peterson LS. Contraceptive use in the United States: 1982-90. Adv Data Feb 14 1995; 260:1-15.
19. Westhoff C, Davis A. Tubal sterilization: focus on the US experience. Fertil Steril May 2000;73(5):913-22.
20. Bakkum-Gamez JN, Langstraat CL, Martin JR, Lemens MA, Weaver AL, Allensworth S, et al. Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma. Gynecol Oncol Jun 2012;125(3):614-20 [Epub 2012 Feb 24].
21. Beard CM, Hartmann LC, Atkinson EJ, O'Brien PC, Malkasian GD, Keeney GL, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol Jan 2000;10(1):14-23.
22. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res Oct 15 1988;48(20):5849-52.
23. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA Dec 15 1993;270(23):2813-8.
24. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol Apr 2013;42(2):579-89.
25. Whittemore AS, Wu ML, Paffenbarger Jr RS, Sarles DL, Kampert JB, Grosser S, et al. Personal and environmental characteristics related to epithelial ovarian cancer, II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol Dec 1988;128(6):1228-40.
26. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol Dec 2005;106(6):1327-34.
27. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol Apr 2009;3(2):165-70 [Epub 2009 Feb 3].
28. Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol Aug 22 2009;22(8):985-8 [Epub 2009 May 1].
29. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci May 2011;108(18):7547-52.
30. Kumar RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol Jul 2011;42(7):918-31.
31. Sandoval C, Fung-Kee-Fung M, Gilks B, Murphy KJ, Rahal R, et al. Examining the use of salpingectomy with hysterectomy in Canada. Curr Oncol Jun 2013;20(3):173-5.
32. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol Jun 2013;129(3):448-51 [Epub 2013 Apr 2].
33. McAlpine, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol Oct 2013; 210(5):471.e1-471.e11.
34. Strandell A, Lindhard A, Waldenström U, Thorburn J. Prophylactic salpingectomy does not impair the ovarian response in IVF treatment. Human Reprod Jun 2001; 16(6):1135-9.
35. Strandell A, Lindhard A, Waldenstrom U, Thorburn J. Hydrosalpinx and IVF outcome: cumulative results after salpingectomy in a randomized controlled trial. Human Reprod Nov 2001;16(11):2403-10.
36. Schuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int Sep 2008;14(3):111-6.